

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 September 2001 (07.09.2001)

PCT

(10) International Publication Number
WO 01/64255 A1

- (51) International Patent Classification⁷: A61K 49/00, 31/54, A61B 10/00
(21) International Application Number: PCT/US01/06318
(22) International Filing Date: 27 February 2001 (27.02.2001)
(25) Filing Language: English
(26) Publication Language: English
(30) Priority Data:
PCT/US00/05387
28 February 2000 (28.02.2000) US
(71) Applicant (for all designated States except US): ZILA, INC. [US/US]; 5227 North Seventh Street, Phoenix, AZ 85014-2800 (US).
(72) Inventors; and
(75) Inventors/Applicants (for US only): BERNAL, Samuel, D. [US/US]; 20000 Calvert Street, Woodland Hills, CA 91367 (US). BURKETT, Douglas, D. [US/US]; 4736 E. Euclid, Phoenix, AZ 85044 (US). GREEN, Ralph, E. [US/US]; 9295 E. Karen Drive, Scottsdale, AZ 85260 (US). ROSE, Seth, D. [US/US]; 613 E. Balboa Drive, Tempe, AZ 85282 (US).
(74) Agent: DRUMMOND, William, H.; Drummond & Duckworth, Suite 500, 4590 MacArthur Boulevard, Newport Beach, CA 92660 (US).
(81) Designated States (national): AU, BR, CA, CN, CZ, HU, IL, IN, JP, KR, MX, NO, NZ, PL, RO, SG, SK, TR, UA, US, ZA.
(84) Designated States (regional): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).
Published:
— with international search report
For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHOD FOR DETECTING AND KILLING EPITHELIAL CANCER CELLS

(57) Abstract: A diagnostic method for detecting cancerous epithelial cells by selectively marking the mitochondria of the cancer cells, by delivering to the epithelium a cationic supravital mitochondrial marking agent. Selective killing of cancerous epithelial cells in the presence of normal cells is effected by delivering a cationic supravital mitochondrial marking agent to epithelial cancer cells. The killing agent can also comprise the reaction product of the marking agent and a cancer chemotherapeutic drug or in admixture with drug.

WO 01/64255 A1